Relevance (Person of Interest)

H&K AG: Capital increase

Retrieved on:

Sunday, April 23, 2023

European Parliament, Financial Services and Markets Act 2000, Financial services, European Union (Withdrawal) Act 2018, European, Person, Article, Finance, Sale, Prospectus, Federal Financial Supervisory Authority, European Economic Area, Council, Relevance (Person of Interest), United Kingdom, Knowledge, Security (finance), EU, Regulation

This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.

Key Points:

This release constitutes neither an offer to sell nor a solicitation to buy securities of the Company.
A public offer of the securities in Germany will be made solely on the basis of the Prospectus yet to be approved by BaFin.
An investment decision regarding the securities of the Company should only be made on the basis of the Prospectus.
The Prospectus will be published promptly upon approval by BaFin and will be available free of charge on the website of the Company (www.heckler-koch.com) under the "Investor Relations – Capital Increase 2023" section.

Canadian Pacific announces results of early tenders of Kansas City Southern notes

Retrieved on:

Monday, April 3, 2023

The CPRC Notes are expected to be issued promptly on or about the second business day following the Expiration Date (the "Settlement Date").

Key Points:

The CPRC Notes are expected to be issued promptly on or about the second business day following the Expiration Date (the "Settlement Date").
CPRL's exercise of control of KCS is not conditioned upon the commencement or completion of the Exchange Offers.
The Registration Statement relating to the CPRC Notes has been filed with the SEC but has not yet become effective.
To validly tender the Old Notes, holders of Old Notes in Canada must complete, sign and submit to the exchange agent a Canadian eligibility statement in the form appended to the Canadian offering memorandum.

EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)

Retrieved on:

Friday, March 24, 2023

BY, AFRICA, Failure, MorphoSys, Financial Services and Markets Act 2000, Financial services, Person, OR, AMERICA, Finance, Sale, EUR, ITS, ANY, Relevance (Person of Interest), ISIN, United Kingdom, Security (finance), Bond

MorphoSys AG (the “Company”) hereby announces that it has repurchased outstanding convertible bonds due 2025 issued by MorphoSys AG (ISIN DE000A3H2XW6) (the “Bonds”), via a modified reverse Dutch auction procedure announced on 23 March 2023.

Key Points:

MorphoSys AG (the “Company”) hereby announces that it has repurchased outstanding convertible bonds due 2025 issued by MorphoSys AG (ISIN DE000A3H2XW6) (the “Bonds”), via a modified reverse Dutch auction procedure announced on 23 March 2023.
At the close of the modified reverse Dutch auction procedure, the Company has agreed to purchase Bonds representing EUR 62.9 million in aggregate principal amount (approximately 19 % of the outstanding principal amount).
Following the settlement of the repurchase which is expected to occur on or around 30 March 2023, an aggregate principal amount of the Bonds of EUR 262.1 million will be outstanding.
Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

EQS-News: MorphoSys AG invites all eligible holders to offer to sell for cash their convertible bonds due 2025 (ISIN DE000A3H2XW6)

Retrieved on:

Thursday, March 23, 2023

Communication, Failure, Financial Services and Markets Act 2000, Financial services, Person, Clinical trial, Cancer, Risk, Finance, Judgement, Sale, Patient, Annual report, Relevance (Person of Interest), United Kingdom, MorphoSys, Bond

Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Key Points:

Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.
This publication is not an extension of a tender offer in the United States for securities of the Company.
A tender offer for the sale of Bonds is not being made within the United States or to, or for the account or benefit of, persons located or resident in the United States.
This document is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons.

DEUTSCHE TELEKOM INTERNATIONAL FINANCE B.V. ANNOUNCES EARLY PARTICIPATION RESULTS AND AN INCREASE IN THE OFFER CAP OF CASH TENDER OFFERS FOR TWO SERIES OF ITS U.S. DOLLAR NOTES

Retrieved on:

Friday, March 10, 2023

NEW YORK, March 10, 2023 /PRNewswire/ -- Further to its launch announcement on February 24, 2023, Deutsche Telekom International Finance B.V. (the "Company") announces today the early participation results of its invitation to holders of its outstanding: (i) US$1,250,000,000 3.600% Notes due January 2027 (ISIN: US25156PBA03 (Rule 144A) / USN27915AS11(Reg S)) (the "2027 Notes") and (ii) US$1,200,000,000 4.375% Notes due June 2028 (ISIN: US25156PBB85 (Rule 144A) / USN2557FFL33 (Reg S)) (the "2028 Notes"), each guaranteed by Deutsche Telekom AG (the "Parent Company") (the 2027 Notes and the 2028 Notes each being a "Series", and any notes within any such Series being the "Notes", and the eligible holders of any Notes, the "Holders") to tender their Notes for purchase by the Company for cash (each such invitation an "Offer" and together, the "Offers"), on the terms of, and subject to the Offer Cap and the Acceptance Priority Levels (each as defined in an offer to purchase dated February 24, 2023 (the "Offer to Purchase")) and the other conditions contained in, the Offer to Purchase. The Company further announces today an increase in the Offer Cap.

Key Points:

Nothing in this announcement or the Offer to Purchase constitutes an offer of securities in the United States of America.
This announcement and the Offer to Purchase contain important information which must be read carefully before any decision is made with respect to the Offers.
The distribution of this announcement and the Offer to Purchase in certain jurisdictions may be restricted by law.
Any Tenders from a Holder that is unable to make these agreements, acknowledgements, representations, warranties and undertakings may be rejected.

EQS-News: BAUER Aktiengesellschaft: BAUER AG announces new schedule and conditions for capital increase

Retrieved on:

Wednesday, February 22, 2023

Schrobenhausen, Germany – Today, BAUER AG is announcing the new schedule and conditions for the capital increase against cash contributions resolved by the Extraordinary General Meeting on November 18, 2022, as Supplement No.

Key Points:

Schrobenhausen, Germany – Today, BAUER AG is announcing the new schedule and conditions for the capital increase against cash contributions resolved by the Extraordinary General Meeting on November 18, 2022, as Supplement No.
The subscription rights are freely transferrable according to the legal regulations that apply for the no-nominal-value bearer shares.
The price of the subscription rights will be determined on an ongoing basis during the ordinary trading hours.
There are no plans to make a multiple purchase offer to the shareholders, as BAUER AG only anticipates a very low allocation rate for the shareholders due to the described conditions.

Notice of AGM

Retrieved on:

Sunday, January 22, 2023

Annual report, London, Person, London Stock Exchange, Relevance (Person of Interest), Luton Airport, AGM, Hangar, Holding company, Security (finance), EasyJet, Equiniti, Proxy, EU

The AGM Notice is also available on the Company's website at https://corporate.easyjet.com/investors/shareholder-services/shareholder... 3.

Key Points:

The AGM Notice is also available on the Company's website at https://corporate.easyjet.com/investors/shareholder-services/shareholder... 3.
Detailed information on how to join the meeting are set out in the AGM Notice.
Any changes to the AGM arrangements will be published on the Company’s website ( https://corporate.easyjet.com/investors ) and announced through the London Stock Exchange.
Shareholders who own shares whose voting rights will be suspended (and therefore whose votes will not be counted) at the AGM will receive a notice (an "Affected Share Notice") by post from Equiniti, our Registrars, on or around 31 January 2023 notifying them of the suspension of voting rights in respect of their Affected Shares.

Cantourage partners with CannFX to bring medical cannabis from New Zealand to Germany for the first time

Retrieved on:

Tuesday, November 29, 2022

BERLIN, Nov. 29, 2022 /PRNewswire/ -- Cantourage Group SE (FRA: HIGH), a European medical cannabis leader has formed a partnership with New Zealand's leading medical cannabis supplier, CannFX, to bring medical cannabis from New Zealand to Germany for the first time. From today, pharmacies and patients throughout Germany will have access to CannFX's first THC cultivar "Wappa". Cantourage plans to also make the products available in additional European markets, including the UK, in 2023.

Key Points:

Partnership with CannFX, New Zealand's leading cannabis supplier, is a strong addition to the Cantourage platform, which supplies medical cannabis to wholesalers and pharmacies throughout Europe
CannFX's non-irradiated dried flowers is the first New Zealand medical cannabis product to be made available in Germany, with CannFX's 'Wappa' strain now available in pharmacies across Germany
BERLIN, Nov. 29, 2022 /PRNewswire/ -- Cantourage Group SE (FRA: HIGH), a European medical cannabis leader has formed a partnership with New Zealand's leading medical cannabis supplier, CannFX, to bring medical cannabis from New Zealand to Germany for the first time.
CannFX was founded in 2019, with the vision to bring the benefits of New Zealand grown medical cannabis to patients globally.
The company has signed agreements with cultivators in New Zealand to supply global markets with high-quality dried cannabis flowers.
Bastiaan Kramer, CEO of CannFX, comments:"We feel privileged to be the first company to bring New Zealand medical cannabis products to patients and pharmacies inEurope, thanks to our collaboration with Cantourage.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Announces Successful Listing of 2,054,796 Shares

Retrieved on:

Sunday, November 27, 2022

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.

Key Points:

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA.
Vivoryon is pioneering a unique therapeutic approach to overcoming the challenges in Alzheimers disease ("AD") drug development.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines.
Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases.

EQS-News: tonies SE: tonies to launch cash capital increase targeting gross proceeds of up to EUR 60 million

Retrieved on:

Friday, November 11, 2022

These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.

Key Points:

These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the tonies SE.
These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described in this document.
Neither tonies SE nor any other person accepts any responsibility for the accuracy of the opinions expressed in this document or the underlying assumptions.
This release may contain forward looking statements, estimates, opinions and projections with respect to anticipated future performance of tonies SE (forward-looking statements).